Newsroom

AstraZeneca will test using component of Russia’s Sputnik V in clinical trials of its own vaccine against coronavirus

  • Sputnik V is one of the most effective vaccines globally with over 90% efficacy against coronavirus. The unique feature of the Russian vaccine is the use of two different components based on human adenovirus in two separate inoculations in order to deliver genetic material from the spike of the coronavirus into the human body. This approach provides for a stronger and longer-term immune response compared with vaccines using the same component for both inoculations.

  • On November 23, 2020, following results which showed high efficacy for the Sputnik V vaccine, RDIF and the Gamaleya Center offered AstraZeneca the use of one of the two components of the Sputnik V vaccine.

  • AstraZeneca accepted the proposal by RDIF and the Gamaleya Center to use one of the two vectors of the Sputnik V vaccine in additional clinical trials of its own vaccine, which will commence before the end of this year.

Moscow, December 11 2020 – After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Gamaleya Institute on November 23, 2020 offered AstraZeneca to use one of the two components (human adenoviral vectors1) of the Sputnik V vaccine in AstraZeneca’s clinical trials.

AstraZeneca accepted RDIF’s proposal and will begin clinical trials of its vaccine in combination with Sputnik V’s human adenoviral vector type Ad26 by the end of 2020. This research will allow AstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.

Sputnik V is among the world’s most effective and safe vaccines due to its unique technology combining two different human adenoviral vectors providing for a stronger and longer-term immune response compared to vaccines using the same component for both inoculations2.

The regimen with two different adenoviral vectors for a prime and a boost immunization is a unique and ground-breaking discovery of the Gamaleya Center scientists. It helps to completely avoid immunity to the first vector, which forms after the first inoculation and thus to raise efficacy and create long-term immunity. Among the leading COVID-19 vaccines only Sputnik V is using the two-vector technology.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:

“This unique example of cooperation between scientists from different countries in jointly fighting coronavirus will play a decisive role in achieving a final victory over the pandemic globally. Russia’s Sputnik V vaccine against coronavirus gamaleya center is already saving people’s lives in Russia today through a large-scale vaccination programme. The decision by AstraZeneca to carry out clinical trials using one of two vectors of Sputnik V in order to increase its own vaccine’s efficacy is an important step towards uniting efforts in the fight against the pandemic. We welcome the beginning of this new stage of cooperation between vaccine producers. We are determined to develop this partnership in the future and to start joint production after the new vaccine demonstrates its efficacy in the course of clinical trials. We hope that other vaccine producers will follow our example.”


1 - Human adenoviral vector is a common cold virus, which has been with humankind for over 100 000 years. It lacks a gene responsible for reproduction and is used to transport into a cell genetic material from another virus that is being vaccinated against, in this case SARS-COV-2 which causes novel coronavirus infection. The vector as well as genetic material inside it do not pose any hazard to the body.

2 - For example, Pfizer, AstraZeneca, Moderna, Johnson&Johnson as well as other two-dose vaccine producers use the same component for both inoculations in their vaccines.

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru

For additional information contact:

Arseniy Palagin
Russian Direct Investment Fund

Press Secretary
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: [email protected]

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133

Message has been successfully sent!

Thank you!
You have been subscribed